Cardiopulmonary complications of ergot-derivative dopamine agonists

J Clin Psychiatry. 2004 Oct;65(10):1429-30; author reply 1430. doi: 10.4088/jcp.v65n1020b.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Bromocriptine / adverse effects
  • Cabergoline
  • Dopamine Agonists / adverse effects*
  • Dopamine Agonists / therapeutic use
  • Dose-Response Relationship, Drug
  • Ergolines / adverse effects*
  • Ergolines / therapeutic use
  • Heart Valve Diseases / chemically induced*
  • Heart Valve Diseases / epidemiology
  • Humans
  • Hyperprolactinemia / chemically induced*
  • Hyperprolactinemia / drug therapy*
  • Pergolide / adverse effects
  • Pulmonary Fibrosis / chemically induced*
  • Pulmonary Fibrosis / epidemiology
  • Risperidone / adverse effects*
  • Risperidone / therapeutic use

Substances

  • Antipsychotic Agents
  • Dopamine Agonists
  • Ergolines
  • Pergolide
  • Bromocriptine
  • Risperidone
  • Cabergoline